BiomX Inc. Reports Q3 2024 Financial Turnaround - Markets Insider

1 day ago · Biomx Inc. ( (PHGE) ) has released its Q3 earnings. Here is a breakdown of the information Biomx Inc. presented to its investors. ... BiomX Inc. Reports Q3 2024 Financial …

CouponFollow Extension

$24
OFF

BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net …

1 week from now

1 day ago · Cash Balance: $24.7 million as of September 30, 2024, down from $30.7 million as of December 31, 2023. Research and Development Expenses: $7.3 million for Q3 2024, up from …

yahoo.com

$9
OFF

BiomX Inc. Q3 2024 Financial Results And Business Updates

1 week from now

2 days ago · Financial Highlights. For the third quarter of 2024, BiomX reported a net income of $9.6 million, a significant turnaround from a net loss of $7.9 million in the same period of 2023. …

tradingview.com

4%
OFF

New Jersey MarketBeats | US | Cushman & Wakefield

1 week from now

Oct 8, 2024 · Financial Services; Legal; View All Industries; ... Q3 2024 New Jersey Industrial Report. In New Jersey industrial market, leasing grew by 19.4% quarter-over-quarter (QOQ), …

cushmanwakefield.com

62%
OFF

USA Equities Reports Strong Q3 2024 Financial Growth - Markets …

1 week from now

2 days ago · USA Equities ( (USAQ)) has provided an announcement. QHSLab, Inc. reported a remarkable Q3 2024 with a 62% revenue surge, showcasing its growth in digital health and …

businessinsider.com

4%
OFF

Motorsport Games Reports Q3 2024 Financial Growth - Markets …

1 week from now

1 day ago · Motorsport Games Reports Q3 2024 Financial Growth. TipRanks. Nov. 14, 2024, 09:58 PM ... marking a financial turnaround. Revenue increased by 6.4% to $1.8 million, and …

businessinsider.com

$50000
OFF

QHSLab, Inc. (OTCQB: USAQ) Reports Record Q3 2024 ... - Markets …

1 week from now

2 days ago · Net Income Turnaround: Q3 2024 saw net income of just under $50,000, a sharp recovery from an $82,000 loss in Q3 2023. Year-to-date net income reached approximately …

businessinsider.com

FAQs about BiomX Inc. Reports Q3 2024 Financial Turnaround - Markets Insider Coupon?

What did biomx announce in the third quarter of 2024?

In the third quarter of 2024, BiomX Inc. announced the completion of patient enrollment for the Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO) and resolved manufacturing delays for BX004 in cystic fibrosis (CF), setting the stage for upcoming trial results. ...

What happens to biomx shares after a merger?

As a result of the stockholder vote, each share of Series X Preferred Stock issued in the Merger and the private placement was converted into 1,000 shares of BiomX common stock, subject to certain beneficial ownership limitations set by certain investors in the Financing. ...

What time will biomx host a conference call & webcast?

Conference Call and Webcast Details BiomX will host a conference call and webcast on August 15, 2024, at 8:00 a.m. ET to discuss its second quarter 2024 financial results and to provide a corporate update. Conference Call Dial-In Information ...

Where can I find information about biomx?

For more information, please visit www.biomx.com, the content of which does not form a part of this press release. This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. ...

Who is biomx?

BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. ...

What is biomx preparing for a Phase 2b trial?

BiomX anticipates initiating a Phase 2b trial of BX004 in CF patients with chronic P. aeruginosa pulmonary infections, with results expected in the third quarter of 2025. BX211- personalized phage treatment for patients with diabetic foot osteomyelitis (“DFO”) associated with Staphylococcus aureus (S. aureus) ...